Long-Term Prescription of α-Blockers Decrease the Risk of Recurrent Urolithiasis Needed for Surgical Intervention-A Nationwide Population-Based Study

摘要

Purposeα1 receptors and subtypes have been confirmed to distribute in human pelvis and calyces recently. As used in ureteral stones, α-blocker treatment may facilitate kidney stone passage and long-term prescription of α-blocker may decrease the risk of recurrent urolithiasis. The aim of this study is to determine if use of α-blockers 180 days or more can decrease the risk of recurrent urolithiasis needed for surgical intervention.